Under a definitive agreement signed between PerkinElmer and Tulip Diagnostics, the former intends to acquire the latter in order to expand its infectious disease screening capabilities.

PerkinElmer is an imaging and informatics solutions provider, while Tulip is an in-vitro diagnostics developer.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Medical diagnosis device manufacturer, Welch Allyn, intends to acquire Mortara Instrument, a manufacturer of diagnostic cardiology, for a cash consideration of $300m.

"The transaction included an upfront payment from Roche and additional earn-out payments subject to achieving certain development and commercial milestones."

The acquisition, which is expected to be completed on or before 9 April 2017, will strengthen the acquirer company’s business with the addition of the target company’s expertise in diagnostic cardiology and patient monitoring offerings and its ability to integrate with electronic medical record (EMR) systems.

Roche Holdings has completed the acquisition of ForSight VISION4 from ForSight Labs, an ophthalmic incubator based in California, US.

The acquisition enables Roche to expand its exclusive access to ForSight’s Port Delivery System (PDS) technology for long acting delivery of eye therapeutics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The transaction included an upfront payment from Roche and additional earn-out payments subject to achieving certain development and commercial milestones.

Specialty medical devices manufacturer, Integra LifeSciences, will acquire Derma Sciences for a cash consideration of approximately $204m, and $32 a share for its outstanding shares of series A convertible preferred stock and $48 a share for its series B convertible preferred stock.

Funded by Integra’s existing credit facility, the acquisition will expand the company’s regenerative technology capabilities and also add complementary line of advanced wound care products including amniotic tissue-based products, which can be commercialised using the company’s existing sales channel.